Year 2023 / Volume 115 / Number 8
Editorial
Should we incorporate long-term use of albumin for patients with decompensated cirrhosis into our daily clinical practice?

414-417

DOI: 10.17235/reed.2022.9216/2022

Juan Uriz Otano, Soraya López López, Conrado Fernández Rodríguez,

Abstract
Ascites is the most frequent complication of cirrhosis and carries with it a high morbidity and mortality. The results of the ANSWER study and others like it open the possibility of considering the prolonged administration of albumin, as an effective and safe treatment in patients with decompensated cirrhosis, capable of modifying their natural history, allowing a better control of ascites, a lower incidence of other complications of portal hypertension, and an increased survival. For this, it is necessary the administration of albumin with the appropriate dose and duration to restore their physiological conditions. However, new studies are needed to confirm the efficacy and safety of prolonged administration of albumin in patients with decompensated cirrhosis and to identify the subpopulation of patients that benefit the most, the appropriate dose and duration, serum-clinical markers of response, the necessary logistics to facilitate its application and its cost-effectiveness in the different health systems.
Share Button
New comment
Comments

02/08/2023 20:00:12
I agree ,we need more studies about the long use of albumin in descompensated advanced liver disease


References
1. Caraceni P, O'Brien A, Gines P . Long-term albumin treatment in patients with cirrhosis and ascites.. J Hepatol. 2022; 76:1306-1317.
2. Italian Association for the Study of the Liver (AISF); Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. Dig Liver Dis. 2016;48:4-15
3. Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69(6):1127-1138
4. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-460.
5. Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639–645.
6. Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006;12:1403–1407.
7. Caraceni P, Riggio O, Angeli P, et al. Longterm albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018;391:2417–2429.
8. Caraceni P, Tufoni M, Zaccherini et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol 2021;74:340-349.
9. Di Pascoli M, Fasolato S, Piano S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 2019;39:98–105.
10. Solà E, Solé C, Simón-Talero M, Martín-Llahí M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol2018;69:1250–1259.
11. China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021;384:808–817
Related articles

Editorial

Treatment of portal vein thrombosis in cirrhosis patients

DOI: 10.17235/reed.2023.9800/2023

Editorial

AKI-HRS, more than a name change for type-1 hepatorenal syndrome

DOI: 10.17235/reed.2023.9677/2023

Letter

Tolvaptan in portal hypertension: real life experience

DOI: 10.17235/reed.2022.9145/2022

Editorial

New actors come into play against hepatitis delta

DOI: 10.17235/reed.2022.9050/2022

Letter

Hemoperitoneum due to rupture of intra-abdominal varices

DOI: 10.17235/reed.2022.8937/2022

Letter

Cirrhotic pattern in advanced hepatic sarcoidosis

DOI: 10.17235/reed.2021.8446/2021

Digestive Diseases Image

Giant cystic hepatocarcinoma in the absence of cirrhosis

DOI: 10.17235/reed.2021.8313/2021

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Case Report

Using octreotide for refractory ascites after liver transplantation

DOI: 10.17235/reed.2019.6316/2019

Review

Risk stratification and treatment of primary biliary cholangitis

DOI: 10.17235/reed.2018.5662/2018

Case Report

Long-evolution ascites in a patient with constrictive pericarditis

DOI: 10.17235/reed.2015.3728/2015

Citation tools
Uriz Otano J, López López S, Fernández Rodríguez C. Should we incorporate long-term use of albumin for patients with decompensated cirrhosis into our daily clinical practice?. 9216/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1737 visits.
This article has been downloaded 398 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/09/2022

Accepted: 05/10/2022

Online First: 01/12/2022

Published: 26/07/2023

Article Online First time: 73 days

Article editing time: 310 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology